A grassroots petition signed by more than four thousand Australian dog owners is asking the Australian and New Zealand College of Veterinary Scientists to publish a formal position statement on canine longevity drugs well ahead of any Australian regulatory decision. The owners behind the petition argue that Australian general practitioners need authoritative professional guidance to answer the questions they're already getting in the consult room — even though no longevity drug is yet legally prescribable in Australia.

The college has not committed to a publication date but has confirmed receipt of the petition and indicated that an internal working group has been considering a statement for several months. That working group reportedly includes representatives from small animal medicine, geriatric medicine, and the college's ethics committee, with consulting input from researchers at two Australian veterinary schools.

The Australian regulatory timeline for any imported longevity drug runs through the APVMA, which historically waits for at least one major international approval before committing to its own review. That means Australian owners are likely to be waiting six to twelve months behind the first U.S. or EU approval — long enough that local professional guidance, if published in advance, could meaningfully shape how owners think about the drugs when they do arrive.

The petition's organizers have been deliberately measured in their public communications. They're not advocating for a particular drug or for early access; they're advocating for clarity. As one signatory wrote in the comments section: "I'm not asking the college to tell me to put my dog on this. I'm asking them to tell my vet what to say to me when I ask."

That distinction — guidance for the practitioner conversation rather than guidance for prescribing — is one of the under-discussed aspects of how a longevity drug actually rolls out across a country. We're tracking similar petitions and professional society responses in five other markets and will publish a comparison piece once enough data is in.